On page 4990, in the paragraph beginning “The cumulative incidence of relapse,” the cumulative incidence of relapse with CPX-351 should be 0.29, not 0.30. The hazard ratio (HR) should be 0.69, not 0.72. The 95% confidence interval (CI) should be 0.38 to 1.25, not 0.40 to 1.30.

In Figure 1B (page 4991), the data in the columns labeled “Events/N (%)” under “CPX-351” and “7 + 3” have been updated. In Figure 1C, the Events/N ratio for “CPX-351” should be 15/52, not 16/53, “HR (95% CI)” should be 0.69 (0.38-1.25), not 0.72 (0.40-1.30), the blue “7+3” curve has been updated, and the first “at risk” number for “CPX-351” should be 52, not 53. In Figure 1D, the Events/N ratio for “CPX-351” should be 15/52, not 15/53, and the first "at risk" number for "CPX-351" should be 52, not 53. In the legend for Figure 1, the sentence, “One patient who achieved a best response of CR relapsed before alloHCT” should read, “One patient who achieved a best response of CR, relapsed before alloHCT and is not included in the analyses for cumulative incidence of relapse or NRM.” This sentence should follow “(D) Cumulative incidence of NRM.” The corrected figure is shown below.
Figure 1.
Post-alloHCT outcomes. (A) OS landmarked from the alloHCT date. Reprinted from Lancet Hematology7 with permission from Elsevier. (B) Subgroup analyses of OS landmarked from the alloHCT date. “N” denotes the number of patients who proceeded to alloHCT. (C) Cumulative incidence of relapse. (D) Cumulative incidence of NRM. One patient who achieved a best response of CR, relapsed before alloHCT and is not included in the analyses for cumulative incidence of relapse or NRM. CMML, chronic myelomonocytic leukemia; HMA, hypomethylating agent.
View largeDownload PPT

Post-alloHCT outcomes. (A) OS landmarked from the alloHCT date. Reprinted from Lancet Hematology7 with permission from Elsevier. (B) Subgroup analyses of OS landmarked from the alloHCT date. “N” denotes the number of patients who proceeded to alloHCT. (C) Cumulative incidence of relapse. (D) Cumulative incidence of NRM. One patient who achieved a best response of CR, relapsed before alloHCT and is not included in the analyses for cumulative incidence of relapse or NRM. CMML, chronic myelomonocytic leukemia; HMA, hypomethylating agent.

Figure 1.
Post-alloHCT outcomes. (A) OS landmarked from the alloHCT date. Reprinted from Lancet Hematology7 with permission from Elsevier. (B) Subgroup analyses of OS landmarked from the alloHCT date. “N” denotes the number of patients who proceeded to alloHCT. (C) Cumulative incidence of relapse. (D) Cumulative incidence of NRM. One patient who achieved a best response of CR, relapsed before alloHCT and is not included in the analyses for cumulative incidence of relapse or NRM. CMML, chronic myelomonocytic leukemia; HMA, hypomethylating agent.
View largeDownload PPT

Post-alloHCT outcomes. (A) OS landmarked from the alloHCT date. Reprinted from Lancet Hematology7 with permission from Elsevier. (B) Subgroup analyses of OS landmarked from the alloHCT date. “N” denotes the number of patients who proceeded to alloHCT. (C) Cumulative incidence of relapse. (D) Cumulative incidence of NRM. One patient who achieved a best response of CR, relapsed before alloHCT and is not included in the analyses for cumulative incidence of relapse or NRM. CMML, chronic myelomonocytic leukemia; HMA, hypomethylating agent.

Close modal
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2023